Narcotic drug formulations with decreased abuse potential
View Patent ↗The present application relates to novel narcotic formulations having a decreased injection abuse potential In a representative embodiment, the formulation comprises methadone hydrochloride (6-dimethylamino-4,4-diphenylheptan-3-one, a synthetic opiod), meglumine, cellulose, lactose, and magnesium stearate The application further illustrates methods for making the contemplated formulations.
1. An oral drug formulation for reducing potential for abuse, the formulation comprising: a pharmaceutically acceptable salt of a narcotic drug, wherein the narcotic drug has a chemical structure that includes at least one positively charged protonated amine; and an alkalizing agent for reducing the solubility of the narcotic drug in a non-acidic solution, wherein the alkalizing agent comprises an amine containing compound selected from the group consisting of meglumine, monoethanolamine, diethanolamine and triethanolamine; wherein the alkalizing agent is present in a molar ratio between 0.1 and 1.5 mol of the positively charged protonated amine/mol alkalizing agent.
2. The drug formulation as defined in claim 1 , wherein said narcotic drug is an opioid.
3. The drug formulation as defined in claim 2 , wherein said opioid is selected from the group consisting of oxycodone, morphine, hydromorphone, hydrocodone, oxymorphone, codeine, and methadone.
4. The drug formulation as defined in claim 1 , wherein said alkalizing agent is meglumine.
5. The drug formulation as defined in claim 4 , wherein the narcotic drug and meglumine are present in a molar ratio of less than 1.5 mol narcotic drug/mol meglumine.
6. The drug formulation as defined in claim 5 , wherein the narcotic drug is methadone.
7. The drug formulation as defined in claim 1 , further comprising one or more of the following: a compressible tablet diluent and disintegrant, a compressible tablet filler, a tablet lubricant and a colorant.
8. The drug formulation as defined in claim 7 , wherein: the pharmaceutically acceptable salt of the narcotic drug is methadone hydrochloride, and the methadone hydrochloride is present in an amount between 1-30 wt %, the alkalizing agent is present in an amount between 0.5-30 wt %, the compressible tablet diluent and disintegrant is present in an amount between 20-80 wt %, the compressible tablet filler is present in an amount between 20-80 wt % and the tablet lubricant is present in an amount between 0.1-5 wt %.
9. The drug formulation as defined in claim 8 , wherein: the methadone hydrochloride is present in an amount between 1-5 wt %, and the alkalizing agent is present in an amount between 0.5-10 wt %.
10. The drug formulation as defined in claim 8 , wherein the alkalizing agent is meglumine.
11. The drug formulation as defined in claim 1 comprising methadone hydrochloride and meglumine, wherein methadone extraction with water is less than about 10% of the total methadone available in tablet form.
12. The drug formulation as defined in claim 1 comprising methadone hydrochloride and meglumine, wherein methadone extraction in alcoholic solutions is less than about 50% of the total methadone available in tablet form.
13. The drug formulation as defined in claim 11 , wherein the methadone hydrochloride is present in an amount between 1-30 wt %, the meglumine is present in an amount between 0.5-30 wt %, a compressible tablet diluent and disintegrant is present in an amount between 20-80 wt %, a compressible tablet filler is present in an amount between 20-80 wt % and a tablet lubricant is present in an amount between 0.1-5 wt %.
14. The drug formulation as defined in claim 13 , wherein the methadone hydrochloride is present in an amount between 1-5 wt %, the alkalizing agent is present in an amount between 0.5-10 wt %.
15. The drug formulation as defined in claim 11 wherein more than 70 wt % of the methadone hydrochloride dissolves in 15 minutes in USP simulated gastric fluid.
16. The drug formulation as defined in claim 11 having an in vitro dissolution rate of the methadone hydrochloride, when measured with USP apparatus Type II at 100 rpm in USP simulated gastric fluid, between about 5 wt % and about 30 wt % after 5 minutes; between about 40 wt % and about 80 wt % after 10 minutes; or between about 70 wt % and about 100 wt % after 15 minutes.
17. The drug formulation as defined in claim 1 comprising methadone hydrochloride and meglumine, wherein, when the formulation is crushed and exposed to small volume of water with stirring for 5 minutes at room temperature, less than about 5% by weight of the pharmaceutically active agent originally present in the formulation before it was crushed is released into the water.
18. The drug formulation as defined in claim 1 comprising meglumine, wherein, when the formulation is crushed and exposed to a small volume of solution containing 95% (v/v) ethanol with stirring for 5 minutes at room temperature, less than about 50% by weight of the pharmaceutically active agent originally present in the formulation before it was crushed is released into the aqueous solution.
19. A process for manufacturing a drug formulation as defined in claim 1 , which process includes a step of combining the constituents of the drug formulation through dry blending, aqueous granulation, or dry granulation, wherein the formulation is in the form of a capsule, caplet, pill or a compressed tablet.
20. The drug formulation as defined in claim 9 , wherein the alkalizing agent is meglumine.
21. The drug formulation as defined in claim 12 , wherein the methadone hydrochloride is present in an amount between 1-30 wt %, the meglumine is present in an amount between 0.5-30 wt %, a compressible tablet diluent and disintegrant is present in an amount between 20-80 wt %, a compressible tablet filler is present in an amount between 20-80 wt % and a tablet lubricant is present in an amount between 0.1-5 wt %.
22. The drug formulation as defined in claim 21 , wherein the methadone hydrochloride is present in an amount between 1-5 wt %, the alkalizing agent is present in an amount between 0.5-10 wt %.
23. The drug formulation as defined in claim 12 wherein more than 70 wt % of the methadone hydrochloride dissolves in 15 minutes in USP simulated gastric fluid.
24. The drug formulation as defined in claim 12 having an in vitro dissolution rate of the methadone hydrochloride, when measured with USP apparatus Type II at 100 rpm in USP simulated gastric fluid, between about 5 wt % and about 30 wt % after 5 minutes; between about 40 wt % and about 80 wt % after 10 minutes; or between about 70 wt % and about 100 wt % after 15 minutes.
25. A method for reducing potential for abuse of a narcotic drug, the method comprising: providing to a patient an oral formulation of the drug, wherein the formulation comprises: a pharmaceutically acceptable salt of the narcotic drug comprising a chemical structure that includes at least one positively charged protonated amine; and an alkalizing agent for reducing the solubility of the narcotic drug in a non-acidic solution, the alkalizing agent comprising: an amine containing compound selected from the group consisting of meglumine, monoethanolamine, diethanolamine and triethanolamine; wherein the alkalizing agent is present in a molar ratio between 0.1 and 1.5 mol of the positively charged protonated amine/mol alkalizing agent.
26. The method according to claim 25 , wherein the narcotic drug is methadone.
27. The method according to claim 25 , wherein the alkalizing agent is meglumine.
28. The method according to claim 25 , wherein the pharmaceutically acceptable salt of the narcotic drug is methadone hydrochloride and the alkalizing agent is meglumine, and wherein:
a) methadone extraction with water is less than about 10% of the total methadone available in tablet form;
b) methadone extraction in alcoholic solutions is less than about 50% of the total methadone available in tablet form;
c) more than 70 wt % of the methadone hydrochloride dissolves in 15 minutes in USP simulated gastric fluid;
d) the drug formulation has an in vitro dissolution rate of the methadone hydrochloride, when measured with USP apparatus Type II at 100 rpm in USP simulated gastric fluid, between about 5 wt % and about 30 wt % after 5 minutes; between about 40 wt % and about 80 wt % after 10 minutes; or between about 70 wt % and about 100 wt % after 15 minutes;
e) when the drug formulation is crushed and exposed to small volume of water with stirring for 5 minutes at room temperature, less than about 5% by weight of the methadone originally present in the formulation before it was crushed is released into the water; and/or
f) when the formulation is crushed and exposed to a small volume of solution containing 95% (v/v) ethanol with stirring for 5 minutes at room temperature, less than about 50% by weight of the pharmaceutically active agent originally present in the formulation before it was crushed is released into the aqueous solution.